Literature DB >> 28106465

Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis.

Junqi Wang1, Ruiguo Zhang1.   

Abstract

OBJECTIVE: Amiodarone-induced thyrotoxicosis (AIT) is caused by amiodarone as a side effect of cardiovascular disease treatment. Based on the differences in their pathological and physiological mechanisms, many methods have been developed so far to differentiate AIT subtypes such as colour flow Doppler sonography (CFDS) and 24-h radioiodine uptake (RAIU). However, these methods suffer from inadequate accuracy in distinguishing different types of AITs and sometimes lead to misdiagnosis and delayed treatments. Therefore, there is an unmet demand for an efficient method for accurate classification of AIT.
METHODS: Technetium-99 methoxyisobutylisonitrile (99mTc-MIBI) thyroid imaging was performed on 15 patients for AIT classification, and the results were compared with other conventional methods such as CFDS, RAIU and 99mTcO4 imaging.
RESULTS: High uptake and retention of MIBI in thyroid tissue is characteristic in Type I AIT, while in sharp contrast, low uptake of MIBI in the thyroid tissue was observed in Type II AIT. Mixed-type AIT shows uptake value between Types I and II. MIBI imaging outperforms other methods with a lower misdiagnosis rate.
CONCLUSION: Among the methods evaluated, MIBI imaging enables an accurate identification of Type I, II and mixed-type AITs by showing distinct images for different types of AITs. The results obtained from our selected subjects revealed that MIBI imaging is a reliable method for diagnosis and classification of AITs and MIBI imaging has potential in the treatment of thyroid diseases. Advances in knowledge: 99mTc-MIBI imaging is a useful method for the diagnosis of AIT. It can distinguish different types of AITs especially for mixed-type AIT, which is usually difficult to treat. 99mTc-MIBI has potential advantages over conventional methods in the efficient treatment of AIT.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28106465      PMCID: PMC5601526          DOI: 10.1259/bjr.20160836

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  21 in total

Review 1.  Amiodarone-induced thyrotoxicosis.

Authors:  G H Daniels
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

2.  Amiodarone: an effective antiarrhythmic drug with unusual side effects.

Authors:  Lieselot van Erven; Martin J Schalij
Journal:  Heart       Date:  2010-10       Impact factor: 5.994

3.  Could 99mTc-MIBI be used to visualize the apoptotic MCF7 human breast cancer cells?

Authors:  J Vergote; M Di Benedetto; J L Moretti; H Azaloux; J C Kouyoumdjian; M Kraemer; M Crepin
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2001-05       Impact factor: 1.770

4.  The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.

Authors:  L Tomisti; C Urbani; G Rossi; F Latrofa; C Sardella; L Manetti; I Lupi; C Marcocci; L Bartalena; O Curzio; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2016-01-13       Impact factor: 4.256

Review 5.  Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?

Authors:  Maria Laura Tanda; Fausto Bogazzi; Enio Martino; Luigi Bartalena
Journal:  Eur J Endocrinol       Date:  2008-07-30       Impact factor: 6.664

6.  Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis.

Authors:  David A Pattison; James Westcott; Meir Lichtenstein; H B Toh; Dishan Gunawardana; Nathan Better; Simon Forehan; Dinesh Sivaratnam
Journal:  Nucl Med Commun       Date:  2015-04       Impact factor: 1.690

Review 7.  Approach to the patient with amiodarone-induced thyrotoxicosis.

Authors:  Fausto Bogazzi; Luigi Bartalena; Enio Martino
Journal:  J Clin Endocrinol Metab       Date:  2010-06       Impact factor: 5.958

8.  Incidence, Clinical Course, and Risk Factors of Amiodarone-Induced Thyroid Dysfunction in Japanese Adults With Congenital Heart Disease.

Authors:  Daiji Takeuchi; Kei Honda; Tokuko Shinohara; Kei Inai; Keiko Toyohara; Toshio Nakanishi
Journal:  Circ J       Date:  2015-05-27       Impact factor: 2.993

Review 9.  Effects of amiodarone therapy on thyroid function.

Authors:  Janna Cohen-Lehman; Peter Dahl; Sara Danzi; Irwin Klein
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

Review 10.  Amiodarone-induced thyrotoxicosis: a review.

Authors:  Wendy Tsang; Robyn L Houlden
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

View more
  3 in total

1.  Diagnosis and Clinical Course of Three Adolescents with Amiodarone-Induced Hyperthyroidism.

Authors:  Julia Gesing; Julia Hoppmann; Roman Gebauer; Roland Pfäffle; Astrid Bertsche; Wieland Kiess
Journal:  Pediatr Cardiol       Date:  2018-09-21       Impact factor: 1.655

2.  Absent 99mTc-MIBI Uptake in the Thyroid Gland during Early Phase of Parathyroid Scintigraphy in Patients with Primary and Secondary Hyperparathyroidism.

Authors:  Anamarija Jovanovska; Bojana Stoilovska; Magdalena Mileva; Daniela Miladinova; Venjamin Majstorov; Ana Ugrinska
Journal:  Open Access Maced J Med Sci       Date:  2018-05-10

3.  99mTc-labeled nanocolloid drugs: development methods.

Authors:  Vladimir Sadkin; Viktor Sкuridin; Evgeny Nesterov; Elena Stasyuk; Alexander Rogov; Natalya Varlamova; Roman Zelchan
Journal:  Sci Rep       Date:  2020-08-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.